Carbamazepine-induced immune thrombocytopenia confirmed by modified MASPAT test

Weiyuan Chen; Xiaoying Lv; Ruiming Rong; Boting Wu

doi:10.1016/j.transci.2021.103228

Carbamazepine-induced immune thrombocytopenia confirmed by modified MASPAT test

Transfus Apher Sci. 2021 Dec;60(6):103228. doi: 10.1016/j.transci.2021.103228. Epub 2021 Aug 2.

Authors

Weiyuan Chen¹, Xiaoying Lv¹, Ruiming Rong², Boting Wu³

Affiliations

¹ Department of Transfusion, Zhongshan Hospital Xiamen Branch, Fudan University, Xiamen, 361015, China.
² Department of Transfusion, Zhongshan Hospital Xiamen Branch, Fudan University, Xiamen, 361015, China; Department of Transfusion, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
³ Department of Transfusion, Zhongshan Hospital Fudan University, Shanghai, 200032, China. Electronic address: wu.boting@zs-hospital.sh.cn.

PMID: 34364794
DOI: 10.1016/j.transci.2021.103228

Abstract

A 76-year-old man suffering post-herpetic neuralgia developed severe thrombocytopenia 15 days after the administration of carbamazepine. Carbamazepine-dependent platelet antibodies were proved to be present in the patient's serum by a modified Monoclonal Antibody Solid-phase Platelet Antibody Test (MASPAT), and the diagnosis of carbamazepine-induced immune thrombocytopenia was confirmed. For the patient, carbamazepine should be advised to be avoided permanently. The present report advocated the application of a modified MASPAT test for the detection of carbamazepine-dependent platelet antibodies.

Keywords: Carbamazepine; Drug-induced immune thrombocytopenia.

MeSH terms

Aged
Carbamazepine / adverse effects*
Humans
Male
Purpura, Thrombocytopenic, Idiopathic / chemically induced*

Substances

Carbamazepine